CRISPR Therapeutics AG Annual Weighted Average Number of Shares Outstanding, Diluted from 2017 to 2023

Taxonomy & unit
us-gaap: shares
Description
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Summary
CRISPR Therapeutics AG quarterly/annual Weighted Average Number of Shares Outstanding, Diluted history and growth rate from 2017 to 2023.
  • CRISPR Therapeutics AG Weighted Average Number of Shares Outstanding, Diluted for the quarter ending September 30, 2024 was 85.2M shares, a 7.33% increase year-over-year.
  • CRISPR Therapeutics AG annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 79.2M shares, a 1.9% increase from 2022.
  • CRISPR Therapeutics AG annual Weighted Average Number of Shares Outstanding, Diluted for 2022 was 77.7M shares, a 3.29% decline from 2021.
  • CRISPR Therapeutics AG annual Weighted Average Number of Shares Outstanding, Diluted for 2021 was 80.4M shares, a 21.9% increase from 2020.
Weighted Average Number of Shares Outstanding, Diluted, Annual (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 79.2M +1.47M +1.9% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-21
2022 77.7M -2.65M -3.29% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-21
2021 80.4M +14.4M +21.9% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-21
2020 65.9M +9.02M +15.8% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-21
2019 56.9M +8.97M +18.7% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-15
2018 48M +7.91M +19.7% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-16
2017 40.1M Jan 1, 2017 Dec 31, 2017 10-K 2020-02-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.